PMID- 19576120
OWN - NLM
STAT- MEDLINE
DCOM- 20090903
LR  - 20181201
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 48
IP  - 4
DP  - 2009 Apr
TI  - [A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy 
      in type 2 diabetes mellitus].
PG  - 304-7
AB  - OBJECTIVE: To compare the efficacy and tolerability of nateglinide with those of 
      acarbose in Chinese type 2 diabetes mellitus (T2DM) patients. METHODS: This 
      multi-center, randomized, double-blind, parallel-arm study compared the efficacy 
      and tolerability of nateglinide (120 mg, 3/d, n = 119) and those of acarbose (100 
      mg, 3/d, n = 118) during a 12-week treatment in T2DM patients uncontrolled by 
      diet with glycosylated haemoglobin (HbA1c) 6.5% - 11.0%. RESULTS: Monotherapy 
      with nateglinide (120 mg, 3/d) or acarbose (100 mg, 3/d) decreased HbA1c to a 
      similar extent during 12-week treatment. The mean change from baseline to 
      end-point in HbA1c was (-0.90 +/- 0.98)% and (-0.83 +/- 0.81)% in patients 
      receiving nateglinide and acarbose, respectively, with no significant difference 
      between the two groups (P > 0.05). The decrease in fasting plasma glucose (FPG) 
      was similar between nateglinide and acarbose (P > 0.05). The mean change in 
      2-hour postprandial plasma glucose (PG2h) was (-1.45 +/- 2.74) mmol/L and (-2.20 
      +/- 2.21) mmol/L in patients receiving nateglinide and acarbose (P = 0.0017). 
      Body weight was significantly decreased in both groups at the end-point (P < 
      0.05), although the decrease was more with acarbose than nateglinide [(-0.66 +/- 
      1.79) kg vs (-2.06 +/- 2.00) kg, P = 0.0000]. And the proportion of patients 
      experiencing any presumed drug related adverse events was not significantly 
      different between the two groups. CONCLUSIONS: Nateglinide (120 mg, 3/d) is 
      effective and well tolerated in T2DM patients uncontrolled by diet, demonstrating 
      similar HbA1c reductions as compared with acarbose (100 mg, 3/d).
FAU - Pan, Chang-Yu
AU  - Pan CY
AD  - Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China. 
      panchy301@yahoo.com.cn
FAU - Gao, Yan
AU  - Gao Y
FAU - Li, Guang-Wei
AU  - Li GW
FAU - Zhu, Xi-Xing
AU  - Zhu XX
FAU - Gao, Xin
AU  - Gao X
FAU - Liu, Xin
AU  - Liu X
LA  - chi
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Cyclohexanes)
RN  - 41X3PWK4O2 (Nateglinide)
RN  - 47E5O17Y3R (Phenylalanine)
RN  - T58MSI464G (Acarbose)
SB  - IM
MH  - Acarbose/*pharmacology/*therapeutic use
MH  - Adult
MH  - Cyclohexanes/*pharmacology/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - Nateglinide
MH  - Phenylalanine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2009/07/07 09:00
MHDA- 2009/09/04 06:00
CRDT- 2009/07/07 09:00
PHST- 2009/07/07 09:00 [entrez]
PHST- 2009/07/07 09:00 [pubmed]
PHST- 2009/09/04 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2009 Apr;48(4):304-7.